Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 7-day suspension order for the drug license of its Versova-Andheri store in Mumbai. The action was taken by the Food and Drug Administration (FDA), Mumbai, under Rule 65 of the Drugs and Cosmetics Act, 1940. The order was received on July 16, 2025. The company estimates a potential revenue loss of around Rs 7 lakh due to this suspension. No other financial or operational details were disclosed.
The financial impact is minimal — a potential revenue loss of about Rs 7 lakh from one store in Mumbai is immaterial relative to Medplus's overall business. However, recurring license issues or expansion of such actions across multiple stores could raise concerns about compliance standards and operational risk.